Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab

Arnon P Kater, Yanwen Jiang, Brenda Chyla, and John F Seymour

Disclosures: A.P.K. research funding - AbbVie/Roche/Genentech, consultancy - AbbVie, honoraria - AbbVie, travel funding – Roche Y.J. employment and equity ownership – Genentech B.C. employment and equity ownership – AbbVie J.F.S. research funding - AbbVie/Celgene/Janssen/Roche, consultancy - Abbvie/Acerta/Celgene/Janssen/Roche/ Takeda, Speakers’ bureau - AbbVie/Celgene/Roche, travel funding - AbbVie

Contributions: All authors contributed significantly to the design of the analysis, had significant intellectual input into the work, and contributed to writing and editing of the manuscript. A.P.K. and Y.J. performed the analysis. Y.J. wrote the first draft.